Bihani et al. agree with this therapeutic approach, recently reporting that BRD4-induced up-regulation of c-MYC is crucial in mediating everolimus resistance in different models of estrogen receptor-positive breast cancer cells [37]. Here, ESR1 is linked to breast cancer.